TRPV1 in Visceral Pain and Other Visceral Disorders

Avelino, António; Cruz, Francisco

doi:10.1002/9780470588284.ch8

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

2012

Publication Types

Select...

Article1

Book1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Findings of previous studies [39][40][41] suggest that TRPV1 receptors are not involved in the mechanosensory pathway in mice, whereas TRPV4 receptors are. However, ABT-116 has no activity at TRPV4 a in that species; therefore, that mechanism cannot be considered as an explanation of the antinociceptive response to the mechanical noxious stimulus for the drug.…”

Section: Discussionmentioning

confidence: 88%

Comparison of the analgesic efficacy of oral ABT-116 administration with that of transmucosal buprenorphine administration in dogs

Niyom

Mama²,

Rezende³

2012

ajvr

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 88%

Comparison of the analgesic efficacy of oral ABT-116 administration with that of transmucosal buprenorphine administration in dogs

Niyom

Mama²,

Rezende³

2012

ajvr

View full text Add to dashboard Cite

show abstract

Modulation of Urinary Bladder Innervation: TRPV1 and Botulinum Toxin A

Charrua

Avelino

Cruz

2011

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

The persisting interest around neurotoxins such as vanilloids and botulinum toxin (BoNT) derives from their marked effect on detrusor overactivity refractory to conventional antimuscarinic treatments. In addition, both are administered by intravesical route. This offers three potential advantages. First, intravesical therapy is an easy way to provide high concentrations of pharmacological agents in the bladder tissue without causing unsuitable levels in other organs. Second, drugs effective on the bladder, but inappropriate for systemic administration, can be safely used as it is the case of vanilloids and BoNT. Third, the effects of one single treatment might be extremely longlasting, contributing to render these therapies highly attractive to patients despite the fact that the reasons to the prolonged effect are still incompletely understood. Attractive as it may be, intravesical pharmacological therapy should still be considered as a second-line treatment in patients refractory to conventional oral antimuscarinic therapy or who do not tolerate its systemic side effects. However, the increasing off-label use of these neurotoxins justifies a reappraisal of their pharmacological properties.

show abstract

TRPV1 in Visceral Pain and Other Visceral Disorders

Cited by 2 publications

References 139 publications

Comparison of the analgesic efficacy of oral ABT-116 administration with that of transmucosal buprenorphine administration in dogs

Comparison of the analgesic efficacy of oral ABT-116 administration with that of transmucosal buprenorphine administration in dogs

Modulation of Urinary Bladder Innervation: TRPV1 and Botulinum Toxin A

Contact Info

Product

Resources

About